It has been about a month since the last earnings report for GSK (GSK). Shares have added about 8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up ...

We suggest that investors who own GSK's stock remain invested for now, considering its sales and profits are expected to continue improving in the coming years.

Cabenuva, GSK’s long-acting HIV treatment, boasted a near-perfect therapeutic score, but it fell behind Vyvgart in both the commercial and R&D analyses to earn a 3.7 overall.

New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and treatment, with Apretude showing zero HIV acquisitions and Cabenuva ...

It has been about a month since the last earnings report for GSK (GSK). Shares have added about 8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to ...

London, 12 March 2025 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced new data from two implementation studies ...

GSK GSK stock has risen 16.9% year to date compared with an increase of 7.0% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below.

LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s ...

When ViiV Healthcare and Johnson & Johnson launched their once-monthly injectable HIV treatment Cabenuva in 2021, they predicted that patients would prefer that option to the need to take tablets ...

GlaxoSmithKline's pitch to shareholders kicked off this afternoon with an optimistic view of its late-stage pipeline – including some big sales predictions for products like its respiratory ...

Results from the phase IIb study, EMBRACE, demonstrate that N6LS, a bNAb administered every four months, effectively maintained undetectable viral load when combined with cabotegravir long-acting (CAB ...